Medical Devices
Technology
Health
Baxter
$77.189876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$77.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.41 (-0.53%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Baxter and other stocks, options, ETFs, and crypto commission-free!
About
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. Read More The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
CEO
Employees
50,000
Headquarters
Deerfield, Illinois
Founded
1931
Market Cap
39.80B
Price-Earnings Ratio
25.87
Dividend Yield
1.11
Average Volume
3.29M
High Today
$77.68
Low Today
$76.87
Open Price
$77.68
Volume
741.91K
52 Week High
$78.38
52 Week Low
$61.05
Collections
Medical Devices
Technology
Health
Medical
Software Service
US
North America
News
Yahoo FinanceMar 19
Baxter (BAX) Upgraded to Buy: Here's What You Should Know
Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Baxter International (BAX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks ...
Yahoo FinanceMar 19
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
Baxter International Inc. BAX and bioMĂ©rieux recently announced an agreement to develop future biomarkers for prompt identification and treatment of acute kidney injury (âAKIâ) at the International Symposium on Intensive Care and Emergency Medicine. This is expected to boost Baxterâs Acute Therapies business apart from fortifying its foothold in the global renal care market. However, following the announcement, shares of this Zacks Rank #2 (Buy) company fell 0.2% to $76.95 at close. Details about the deal...
BusinessWireMar 19
Baxter and bioMĂ©rieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury
DEERFIELD, Ill. & MARCY LâĂTOILE, France--(BUSINESS WIRE)--Regulatory News: Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMĂ©rieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). The announcement was made at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week. âWeâre committed to improving...
Price Paid on Robinhood
21% Higher
Right Now
52 Week Low
$61.05
Average Price Paid
$63.59
52 Week High
$78.38
Earnings
$0.56
$0.64
$0.72
$0.80
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
â
Actual
Available Apr 25, Pre-Market